ARCHIVES

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

This article is from The Cancer Letter archive.

Vol. 26 No. 12 | December 26, 2003

Download PDF Visit The Full Archive

Related Articles

Appropriations Committees Lean Toward Adding Some To NCI Budget; ACS To Ask Again For $1.5 Billion

April 20, 1984

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

January 25, 2002

Group Chairman Present A Counter-Proposal To NCI Committee

June 12, 1998

Mihich Recommendation for Antigen Development In BRMP Summarized

December 14, 1979

GYN Group: Open Surgery Would Cost More Lives Than Morcellation

July 25, 2014

In Breif: FDA Issues Uterine Cancer-Tamoxifin Warning; Fisher Declined Invitation To Speak At AACR

April 15, 1994